Premium
Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?
Author(s) -
Lehmann Sylvain,
Gabelle Audrey,
Paquet Claire
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.09.003
Subject(s) - university hospital , medicine , art , surgery
New recommendations for Alzheimer’s disease (AD) diagnostic criteria include cerebrospinal fluid (CSF) biomarkers results [1]. This represents a major step forward for AD biological diagnosis which would rely on a decrease of amyloid peptides (Ab42), an increase of tau and phosphorylated-tau (p-tau) proteins in theCSF.Amajor issue is represented by the debate over the definition of a proper CSF “Alzheimer profile” and its optimal use in clinical practice. Most of the studies compared, on prospective or retrospective cohorts, the accuracy of the biomarkers to discriminate AD from non-AD patients, or to predict conversion of mild cognitive impairment (MCI) patients. Many combinations based on either simple ratios or complex algorithms have been evaluated. Recently,Duits et al. [2] reported